Skip to content

The Chemours

US · CC #2748 by market cap Listed 1970
10.88 -0.92 -7.80%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:47

Price chart

Pre-market 11.62 -1.53%
After-hours 11.20 +2.94%
23.1212.4812.482026-05-192026-11-16
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CC?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -7.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 9.7% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall D
ValuationGrowthProfitMomentumHealthAnalyst
Valuation A+

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 10.7x Better than 76%
Price / Sales 0.3x Better than 95%
Growth F

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) -5.3% Better than 12%
Net income CAGR (3Y) -51.6% Better than 3%
Free cash flow CAGR (3Y) -51.5% Better than 4%
Profitability D

How much profit the business keeps from each dollar of sales and capital.

Gross margin 15.5% Better than 12%
Operating margin -0.5% Better than 21%
Net margin -6.6% Better than 18%
Return on equity -90.4% Better than 6%
Return on invested capital -3.9% Better than 23%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -21.9% Better than 28%
6-month return -41.3% Better than 11%
12-month return (ex latest month) 17.6% Better than 56%
Distance below 52-week high 61.4% Better than 10%
Financial Health D

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.8x Better than 50%
Debt to assets 59.5% Better than 9%
Interest coverage 0.0x Better than 24%
Free cash flow / net income 77.3% Better than 25%
Analyst View C+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 33.3% Better than 15%
Upside to average target 55.2% Better than 70%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.02%
1M -2.04%
3M -21.26%
6M -45.73%
YTD +7.39%
1Y +6.49%
3Y -48.14%
5Y -55.70%

Key statistics

Price & volume

Prev close
11.80
Open
11.67
Day range
10.83 - 11.92
Avg price
11.09
Volume
3.14M
Turnover
34.79M
Amplitude
9.20%
52-week range
10.77 - 28.22

Valuation

P/E
-4.23
P/E (TTM)
-10.67
P/B
10.56
EPS
-2.57
Net profit
-386.87M
Net assets
155.05M

Share structure

Market cap
1.64B
Float cap
1.63B
Shares out
150.53M
Float shares
149.60M

Dividend & listing

Dividend (TTM)
0.35
Listing date
1970-01-01
52-week range 1% of range
10.77 28.22

61.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-8.42M net over the window

Short interest

Shares short
14.54M
As of
2026-10-30

Frequently asked questions

What is the current stock price of The Chemours (CC)?

The Chemours last traded at 10.88. This page shows a periodic quote snapshot. Check the displayed quote time.

What is The Chemours's market cap?

About 1.64B.

What is the P/E ratio of The Chemours?

The trailing twelve-month P/E is -10.67, below its own 5-year average of 4.09 — toward the bottom of its historical range (14.43% percentile). See the Valuation tab for the full history.

Does The Chemours pay a dividend?

Yes. The trailing dividend yield is 3.22%. Per-share dividends have risen or held for 7 straight years through 2025. See the Dividends tab for the full payment history.

Is The Chemours a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 16.89, which implies 55.2% upside from the current price. This is not investment advice.

What is The Chemours's StockVane Quant Rating?

The StockVane Momentum strategy currently rates The Chemours a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:47:46 · For reference only, not investment advice and not tailored to your situation.

The Chemours discussion 0 comments

Add a comment